Xanomeline-Trospium (Cobenfy)

What it treats

Cobenfy is FDA-approved for schizophrenia in adults. Its approval in September 2024 was a big moment for psychiatric pharmacology, xanomeline had been sitting on the shelf since the 1990s, when trials for Alzheimer's disease showed it reduced psychotic symptoms but caused too many cholinergic side effects to move forward. Pairing it with trospium changed that calculation.

How it works

Xanomeline activates muscarinic acetylcholine receptors, particularly M1 and M4, which reduces dopamine activity indirectly and quiets psychotic symptoms without any direct dopamine blockade. Trospium is an anticholinergic drug that doesn't cross the blood-brain barrier, so it blocks xanomeline's peripheral cholinergic effects (nausea, sweating, GI upset) without interfering with its central antipsychotic action.

Receptor mechanism (detail)

Xanomeline is a muscarinic M1 and M4 receptor agonist with some activity at M2, M3, and M5. Central M1 and M4 activation appears to reduce dopamine signaling in psychosis-related circuits without direct D2 blockade. Trospium is a peripheral muscarinic antagonist that stays outside the central nervous system, so it counteracts the peripheral cholinergic burden (nausea, sweating, salivation, GI symptoms) without blunting xanomeline's antipsychotic effect. The combination has no meaningful activity at dopamine, serotonin, histamine, or adrenergic receptors.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Starting dose is xanomeline 50 mg with trospium 20 mg, taken twice daily. After several days, the dose is increased to xanomeline 100 mg with trospium 20 mg twice daily, and may be increased further to a maximum of xanomeline 125 mg with trospium 30 mg twice daily depending on response and tolerability. Cobenfy is taken on an empty stomach, at least one hour before or two hours after meals. The prescriber sets and adjusts the dose based on response and side effects.

Safety monitoring

• Blood pressure and heart rate at baseline and periodically. Cobenfy can raise both.
• Liver function tests at baseline and periodically, especially in the first year.
• GI symptom check at each visit, nausea, constipation, and dyspepsia are the most common early complaints.
• Bladder function, trospium can cause urinary retention.
• Metabolic labs at baseline and annually are still worthwhile even though metabolic changes aren't expected the way they are with dopamine-blocking antipsychotics.
• Involuntary-movement screen (AIMS) at baseline. Tardive dyskinesia isn't expected with this mechanism, but AIMS still gives a useful baseline.

Metformin co-commencement: Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues. Cobenfy doesn't block dopamine and doesn't cause the metabolic weight gain typical of the class, so the co-commencement framework doesn't apply. Metformin would only be considered if metabolic issues developed for reasons unrelated to Cobenfy.

Typical titration used in the guideline: 500 mg once daily, then 500 mg twice daily after one week, then 500 mg increments every two weeks as tolerated, up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m². Renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

• Nausea.
• Constipation.
• Dyspepsia (indigestion).
• Vomiting.
• Dry mouth.
• Dizziness.
• Rise in blood pressure and heart rate.
• Excessive sweating in some people.

Serious side effects and warnings

• Urinary retention. Trospium's peripheral anticholinergic effect can cause difficulty urinating, especially in people with prostate enlargement.
• Angle-closure glaucoma. Trospium can precipitate acute angle-closure in people with narrow angles.
• Liver enzyme elevations. Some trial participants had transaminase rises; periodic LFT monitoring is part of the safety framework.
• Blood pressure and heart rate elevations. Not typically severe but tracked at each visit.
• Neuroleptic malignant syndrome hasn't been reported in trials but remains a general class consideration.
• Delirium in older adults is a theoretical concern given the muscarinic activity.

This isn't medical advice. Any concern about a serious side effect should be raised with a prescriber promptly.

Sexual side effects

Sexual side effects aren't a defining feature of Cobenfy the way they are with dopamine-blocking antipsychotics. That's one of its appeals. If sexual side effects appear, it's worth raising with the prescriber.

Weight, appetite, and sleep

Cobenfy doesn't drive appetite the way dopamine-blocking antipsychotics do. Weight tends to hold steady. Sleep is usually minimally affected. That metabolic and body-weight neutrality is one of the main practical advantages.

Starting and dosing basics

This section is general background, not a dosing instruction. Cobenfy comes as capsules containing both xanomeline and trospium in a fixed ratio. Take on an empty stomach, at least one hour before or two hours after meals. Twice-daily dosing.

Missed doses and interactions

If you miss a dose, take it when you remember unless it's within a few hours of the next dose, then skip and carry on. Don't double up.

Trospium interacts with other anticholinergic drugs, so combining Cobenfy with strong anticholinergics (some antihistamines, some overactive-bladder drugs, some psychiatric drugs) may amplify dry mouth, constipation, and urinary retention. Xanomeline has less interaction data available given how new it is. The prescriber and pharmacist need a full list of medications and supplements.

Stopping and tapering

Don't stop Cobenfy abruptly. A prescriber can plan a step-down and, if needed, a transition to another antipsychotic.

Pregnancy and breastfeeding

Cobenfy is new enough that human pregnancy data is very limited. Untreated schizophrenia carries its own risks in pregnancy. Anyone who's pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber. This isn't medical advice.

Cost and generic availability

Cobenfy is brand-only and expensive at launch. Manufacturer patient assistance programs exist. Insurance coverage varies and often requires prior authorization documenting a trial or contraindication of another antipsychotic.

Common questions

Why is Cobenfy such a big deal? Because it works through a completely different mechanism than every other antipsychotic. All the previous drugs, first-generation and atypical alike, block dopamine to some degree. Cobenfy doesn't. That opens up the possibility of treating psychosis without the movement problems, prolactin issues, or metabolic burden of dopamine blockade.

Why is trospium in the pill? Trospium doesn't cross the blood-brain barrier, so it blocks xanomeline's peripheral cholinergic side effects (nausea, sweating, GI symptoms) in the gut without touching xanomeline's antipsychotic effect in the brain. Without trospium, xanomeline had too many side effects to be usable, which is why it stalled in the 1990s. Pairing them made the drug workable.

Does it have tardive dyskinesia risk? Because Cobenfy doesn't block dopamine, tardive dyskinesia isn't expected. It's too new to be certain from long-term data yet, but the mechanism suggests the risk should be much lower than with dopamine-blocking antipsychotics.

Does it cause weight gain? Trial data suggests no significant weight gain. That's a real advantage over most other antipsychotics.

Are there people who shouldn't take Cobenfy? People with severe urinary retention risk, narrow-angle glaucoma, significant liver disease, or GI motility problems should probably avoid it or use it with caution. Older adults may be more sensitive to the anticholinergic effects.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• Am I likely to tolerate the GI side effects during the first week or two?
• How will we track liver function and blood pressure?
• What if my urinary symptoms get worse?
• If we decide to stop it later, how would we transition?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Cobenfy (xanomeline-trospium) prescribing information (2024 approval).
• MedlinePlus, U.S. National Library of Medicine. Xanomeline-trospium.
• National Institute of Mental Health. Mental health medications.
• Kaul I, et al. Efficacy and safety of xanomeline-trospium in schizophrenia. New England Journal of Medicine. 2024.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd edition.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.